knowledge -WSS

knowledge

author：explore 2025-10-06 07:43:46 - browse：55

Brain cancer — Michelle Monje/Stanford University/NIH

Tocagen (TOCA) said Tuesday that a Phase 3 clinical trial involving a novel gene therapy for aggressive brain tumors will continue to a final analysis later this year, following an interim look at patient survival data conducted by independent monitors. Tocagen’s stock price dropped sharply.

The San Diego-based biotech pitched the study’s continuation as an encouraging sign for its gene therapy called Toca 511/Toca FC, which is designed to deliver a localized chemotherapy directly to the site of brain tumors.

“We believe the longer-term follow-up of patients in the final analysis, particularly for those randomized in the second enrollment period, will be important in assessing both primary and secondary endpoints,” said Tocagen CEO Marty Duvall, in a statement.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Immune cells and nerve overgrowth may explain recurring UTI pain

Wikipedia

WSS

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

Germany receives 178 compensation applications from gay servicepeople over discrimination

Medicare drug price negotiation continues, as pharma counteroffers

State of the Union pitch: Bigger Medicare drug price negotiations

Ozempic has benefits for kidney disease as well as diabetes

The untold story of TV’s first prescription drug ad

hotspot

knowledge

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

IVF doctors demand details after CooperSurgical lawsuit

Supreme Court strikes down use of affirmative action

In venture capital firm's success, lessons for turning crisis into profit

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Mega Millions jackpot estimated at record $1.58 billion for Tuesday's drawing

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Astronauts get first look at the spacecraft that will fly them around the moon

Medical leaders decry Supreme Court decision on affirmative action

The untold story of TV’s first prescription drug ad

leisure time

Can Threads overtake X, formerly known as Twitter? Experts weigh in.

Boston man files lawsuit seeking to bankrupt white supremacist group he says assaulted him

NYC struggling to keep up with demand of supporting asylum seekers, Mayor Adams says

Former Georgia lieutenant governor says he received grand jury subpoena

Choosing scientific sides in the fight against Alzheimer's

More regulation could be coming for drug ads

leisure time

entertainment

Wikipedia

leisure time